Compare Pfizer with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs SANOFI INDIA - Comparison Results

PFIZER     Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER SANOFI INDIA PFIZER/
SANOFI INDIA
 
P/E (TTM) x 33.7 34.6 97.5% View Chart
P/BV x 5.7 6.1 93.3% View Chart
Dividend Yield % 0.6 1.4 41.9%  

Financials

 PFIZER   SANOFI INDIA
EQUITY SHARE DATA
    PFIZER
Mar-18
SANOFI INDIA
Dec-18
PFIZER/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs2,3656,840 34.6%   
Low Rs1,6254,630 35.1%   
Sales per share (Unadj.) Rs430.31,203.1 35.8%  
Earnings per share (Unadj.) Rs78.7165.3 47.6%  
Cash flow per share (Unadj.) Rs93.2209.9 44.4%  
Dividends per share (Unadj.) Rs20.0084.00 23.8%  
Dividend yield (eoy) %1.01.5 68.4%  
Book value per share (Unadj.) Rs586.5963.6 60.9%  
Shares outstanding (eoy) m45.7523.03 198.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.64.8 97.3%   
Avg P/E ratio x25.334.7 73.0%  
P/CF ratio (eoy) x21.427.3 78.3%  
Price / Book Value ratio x3.46.0 57.2%  
Dividend payout %25.450.8 50.0%   
Avg Mkt Cap Rs m91,271132,078 69.1%   
No. of employees `0002.63.3 79.7%   
Total wages/salary Rs m3,1434,068 77.3%   
Avg. sales/employee Rs Th7,484.88,393.8 89.2%   
Avg. wages/employee Rs Th1,195.01,232.4 97.0%   
Avg. net profit/employee Rs Th1,369.11,153.0 118.7%   
INCOME DATA
Net Sales Rs m19,68527,708 71.0%  
Other income Rs m1,143897 127.4%   
Total revenues Rs m20,82828,605 72.8%   
Gross profit Rs m5,0036,235 80.2%  
Depreciation Rs m6631,027 64.5%   
Interest Rs m47 60.0%   
Profit before tax Rs m5,4796,098 89.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,8782,292 82.0%   
Profit after tax Rs m3,6013,806 94.6%  
Gross profit margin %25.422.5 112.9%  
Effective tax rate %34.337.6 91.2%   
Net profit margin %18.313.7 133.2%  
BALANCE SHEET DATA
Current assets Rs m24,16715,922 151.8%   
Current liabilities Rs m9,5446,235 153.1%   
Net working cap to sales %74.335.0 212.5%  
Current ratio x2.52.6 99.2%  
Inventory Days Days5564 86.6%  
Debtors Days Days2921 137.6%  
Net fixed assets Rs m9,5147,539 126.2%   
Share capital Rs m458230 198.9%   
"Free" reserves Rs m26,37521,962 120.1%   
Net worth Rs m26,83222,192 120.9%   
Long term debt Rs m250-   
Total assets Rs m36,90029,839 123.7%  
Interest coverage x1,305.5872.1 149.7%   
Debt to equity ratio x00-  
Sales to assets ratio x0.50.9 57.5%   
Return on assets %9.812.8 76.5%  
Return on equity %13.417.2 78.2%  
Return on capital %20.427.5 74.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m227,587 0.3%   
Fx outflow Rs m1,4897,145 20.8%   
Net fx Rs m-1,466442 -331.7%   
CASH FLOW
From Operations Rs m3,3183,739 88.7%  
From Investments Rs m-2,383-731 326.0%  
From Financial Activity Rs m-1,104-1,972 56.0%  
Net Cashflow Rs m-1691,036 -16.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 63.9 60.4 105.8%  
Indian inst/Mut Fund % 7.5 14.4 52.1%  
FIIs % 4.9 14.6 33.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 10.5 225.7%  
Shareholders   85,207 15,184 561.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   SHASUN PHARMA  DR. REDDYS LAB  TORRENT PHARMA  UNICHEM LAB  PROCTER & GAMBLE HEALTH  

Compare PFIZER With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Over 100 Points Down; Banking and IT Stocks Under Pressure(09:30 am)

Asian share markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.9% while the Hang Seng is also down 0.9%.

Related Views on News

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA 2017-18 Annual Report Analysis (Annual Result Update)

Apr 16, 2019 | Updated on Apr 16, 2019

Here's an analysis of the annual report of SANOFI INDIA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Sep 17, 2019 10:45 AM

TRACK PFIZER

PFIZER - PLETHICO PHARMA COMPARISON

COMPARE PFIZER WITH

MARKET STATS